Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, cefalosporanic acid derivatives | 575 | 21593-23-7 |
Dose | Unit | Route |
---|---|---|
4 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 48 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 236.14 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.13 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2.70 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.55 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 1.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 12, 1974 | FDA | APOTHECON |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01DB08 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Septicemia due to Escherichia coli | indication | 9323009 | |
Bacterial septicemia | indication | 10001005 | DOID:0040085 |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Staphylococcal pneumonia | indication | 22754005 | |
Streptococcal septicemia | indication | 29577008 | |
Pneumonia due to Streptococcus | indication | 34020007 | |
Lower respiratory tract infection | indication | 50417007 | |
Klebsiella cystitis | indication | 60867007 | |
Urinary tract infectious disease | indication | 68566005 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Infection due to Escherichia coli | indication | 71057007 | |
Rhinoscleroma | indication | 72409005 | DOID:11336 |
Staphylococcal endocarditis | indication | 73028002 | |
Infection of bone | indication | 111253001 | |
Staphylococcal septicemia | indication | 111821004 | |
Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
Pneumonia | indication | 233604007 | DOID:552 |
Escherichia coli urinary tract infection | indication | 301011002 | |
Proteus urinary tract infection | indication | 301012009 | |
Bacterial endocarditis | indication | 301183007 | |
Streptococcus pyogenes infection | indication | 302809008 | |
Infectious disorder of joint | indication | 363162000 | |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
Skin and Skin Structure Proteus Infection | indication | ||
Streptococcus Osteomyelitis | indication | ||
Staphylococcus Epidermidis Skin and Skin Structure Infection | indication | ||
Streptococcal Endocarditis | indication | ||
Proteus Mirabilis Osteomyelitis | indication | ||
Prevention of Perioperative Infection | indication | ||
Staphylococcus Aureus Urinary Tract Infection | indication | ||
Klebsiella Pneumoniae Osteomyelitis | indication |
Species | Use | Relation |
---|---|---|
Cattle | Mastitis caused by Streptococcus dysgalactiae | Indication |
Cattle | Mastitis caused by Staphylococcus aureus | Indication |
Product | Applicant | Ingredients |
---|---|---|
ToDAY | Boehringer lngelheim Animal Health USA Inc. | 1 |
ToMORROW | Boehringer lngelheim Animal Health USA Inc. | 1 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.39 | acidic |
pKa2 | 5.58 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Mu-type opioid receptor | GPCR | IC50 | 5.34 | WOMBAT-PK | |||||
D(2) dopamine receptor | GPCR | IC50 | 4.66 | WOMBAT-PK | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | IC50 | 6.21 | WOMBAT-PK | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 5.31 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 5.48 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2B | GPCR | IC50 | 4.82 | WOMBAT-PK | |||||
D(3) dopamine receptor | GPCR | IC50 | 4.59 | WOMBAT-PK | |||||
Histamine H2 receptor | GPCR | IC50 | 5.24 | WOMBAT-PK | |||||
Alpha-2C adrenergic receptor | GPCR | IC50 | 4.68 | WOMBAT-PK | |||||
Cannabinoid receptor 1 | GPCR | IC50 | 4.07 | WOMBAT-PK | |||||
D(4) dopamine receptor | GPCR | IC50 | 5.01 | WOMBAT-PK | |||||
Kappa-type opioid receptor | GPCR | IC50 | 5.29 | WOMBAT-PK | |||||
Delta-type opioid receptor | GPCR | IC50 | 5.06 | WOMBAT-PK | |||||
Substance-P receptor | GPCR | IC50 | 4.89 | WOMBAT-PK | |||||
Nischarin | Membrane receptor | IC50 | 4.85 | WOMBAT-PK | |||||
Interstitial collagenase | Enzyme | IC50 | 4.43 | WOMBAT-PK | |||||
Substance-K receptor | GPCR | IC50 | 4.85 | WOMBAT-PK | |||||
Cytochrome P450 3A5 | Enzyme | IC50 | 5.11 | WOMBAT-PK | |||||
Somatostatin receptor type 4 | GPCR | IC50 | 5.17 | WOMBAT-PK | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 4.84 | WOMBAT-PK | |||||
Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | WOMBAT-PK |
ID | Source |
---|---|
4018153 | VUID |
N0000179299 | NUI |
D00908 | KEGG_DRUG |
1294563 | RXNORM |
C0007737 | UMLSCUI |
CHEBI:554446 | CHEBI |
CHEMBL1599 | ChEMBL_ID |
CHEMBL1201043 | ChEMBL_ID |
DB01139 | DRUGBANK_ID |
12191 | IUPHAR_LIGAND_ID |
24356-60-3 | SECONDARY_CAS_RN |
30699 | PUBCHEM_CID |
4396 | MMSL |
d00187 | MMSL |
002721 | NDDF |
004842 | NDDF |
370337008 | SNOMEDCT_US |
6873003 | SNOMEDCT_US |
87303007 | SNOMEDCT_US |
96043002 | SNOMEDCT_US |
D002514 | MESH_DESCRIPTOR_UI |
CHEMBL3989837 | ChEMBL_ID |
2871 | INN_ID |
4018153 | VANDF |
4019670 | VANDF |
97468-37-6 | SECONDARY_CAS_RN |
89B59H32VN | UNII |
None